Evidence library

Is the drug enough on its own?

Good obesity care is supposed to pair medication with real nutrition and lifestyle support. In practice, most people get the drug without any of it. Here is the evidence that the standard exists, that the support works, and that it almost never reaches people.

How to read these grades

Evidence strength

  • Strong evidence (does / reduces / improves)
  • Moderate evidence (probably / likely)
  • Early / weak evidence (may / might)

Tested in GLP-1 users?

  • Tested in GLP-1 users
  • Not tested in GLP-1 users
  • Trial underway

The standard of care is clear: refer everyone with obesity to lifestyle counseling

Strong evidence Not tested in GLP-1 users

Independent expert bodies already recommend that every adult with obesity be offered or referred to intensive behavioral counseling as first-line care, a standard that predates the GLP-1 era. The anchor here is a government review with no industry ties.

What it rests on

  • Curry 2018 (USPSTF) 1

    The US Preventive Services Task Force review that recommends offering or referring every adult with obesity to intensive behavioral counseling. It found about 5 lb (2.4 kg) of added weight loss and better diabetes-risk outcomes, but no mortality or heart benefit. It is government-funded with no industry ties.

    General adults, pre-GLP-1

  • Mozaffarian 2025 advisory 2

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

That counseling works, modestly on its own and more with intensity

Moderate evidence Not tested in GLP-1 users

Structured lifestyle counseling produces real weight loss: a modest amount from a dietitian, and 5 to 10% from full intensive behavioral therapy, with more benefit the more contact people get. The point is that this belongs with the drug, not that lifestyle alone rivals it.

What it rests on

  • Williams 2019 3

    A meta-analysis of trials of dietitian-delivered weight counseling. On its own it produced about 2 lb (1 kg) more loss than usual care, with consistent results across studies. It is cleanly academic-funded.

    Not GLP-1 (clean academic funding)

  • Wadden 2020 4

    A review of lifestyle treatment for obesity. Full intensive behavioral therapy (14 or more sessions over six months) yields about 5 to 10% weight loss, more with more contact, but under 1% of eligible people actually use the covered Medicare benefit.

    Not GLP-1

But almost no one actually gets it, and that is the gap

Strong evidence Mixed / consensus

Despite being the recommended standard, intensive lifestyle counseling is rarely delivered. Uptake of even a covered Medicare benefit is under 1%, and referral pathways barely exist. This is a structural gap in the system, not individual clinicians failing.

What it rests on

  • Wadden 2020 4

    A review of lifestyle treatment for obesity. Full intensive behavioral therapy (14 or more sessions over six months) yields about 5 to 10% weight loss, more with more contact, but under 1% of eligible people actually use the covered Medicare benefit.

    Not GLP-1

  • Curry 2018 (USPSTF) 1

    The US Preventive Services Task Force review that recommends offering or referring every adult with obesity to intensive behavioral counseling. It found about 5 lb (2.4 kg) of added weight loss and better diabetes-risk outcomes, but no mortality or heart benefit. It is government-funded with no industry ties.

    General adults, pre-GLP-1

  • Mozaffarian 2025 advisory 2

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

People on GLP-1s get the drug without the support, before, during, or after

Moderate evidence Tested in GLP-1 users

In practice, most people are handed a GLP-1 with little or no nutrition and lifestyle guidance, even though the trial results everyone quotes were achieved with that support. This is the advisory writing group's clinical observation rather than a measured survey.

What it rests on

  • Mozaffarian 2025 advisory 2

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

Cost, low adherence, and regain make the missing support matter more, not less

Moderate evidence Tested in GLP-1 users

Because these drugs are expensive, most people stop within a year, and stopping brings regain, the surrounding nutrition and lifestyle care is what protects the results. This is the advisory's reasoning built on strong underlying facts, not a trial outcome or a cost-effectiveness proof.

What it rests on

  • Mozaffarian 2025 advisory 2

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

It is solvable: scalable delivery models exist, though the evidence is early

Early / weak evidence Not tested in GLP-1 users

The gap is closable. Models like shared group medical visits may deliver counseling at scale and are linked to better weight outcomes, but the evidence so far is a single retrospective study with conflicted funding and near-zero GLP-1 use, so treat it as promising, not proven.

What it rests on

  • Shibuya 2020 5

    A retrospective study compared shared group medical visits with individual care. The group-visit patients lost more (5.2% vs 1.8% at a year) and got more weight-loss prescriptions, but it is not randomized and is drug-maker funded, and the extra prescribing favors that funder.

    Retrospective, near-zero GLP-1 use

  • Mozaffarian 2025 advisory 2

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

Sources

  1. 1. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults. JAMA. 2018;320(11):1163. doi:10.1001/jama.2018.13022
  2. 2. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023
  3. 3. Williams L, Barnes K, Ball L, Ross L, Sladdin I, Mitchell L. How Effective Are Dietitians in Weight Management? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Healthcare. 2019;7(1):20. doi:10.3390/healthcare7010020
  4. 4. Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. American Psychologist. 2020;75(2):235-251. doi:10.1037/amp0000517
  5. 5. Shibuya K, Ji X, Pfoh ER, et al. Association between shared medical appointments and weight loss outcomes and anti-obesity medication use in patients with obesity. Obesity Science & Practice. 2020;6(3):247-254. doi:10.1002/osp4.406